Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 3/20 | 0.66 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.65 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.65 |
| ▸ | GLP1R | P43220 | 9/20 | 0.64 |
| ▸ | CCKBR | P32239 | 1/20 | 0.64 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.63 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.62 |
| ▸ | TFPI | P10646 | 1/20 | 0.62 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628018 | 1.00 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL719111 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29836025 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628017 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628071 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29750818 | 0.98 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL15787075 | 0.98 | CALCR (0.64) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628084 | 0.97 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL29628152 | 0.96 | CALCR (0.66) | CALCRCRHR1CRHR2GLP1RCCKBR | |
| SCHEMBL30529017 | 0.96 | PTH1R (0.65) | CALCRCRHR1CRHR2GLP1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082647-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | IMMUNGENETICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-118510519-A | Specific doses of phenothiazine compounds for use in the treatment or prevention of Alzheimer's dementia | 免疫基因股份公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023131606-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | IMMUNGENETICS AG (DE) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082647-A1 | SPECIFIC DOSAGE OF PHENOTHIAZINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF ALZHEIMER'S DEMENTIA | PSEN1, PSEN2, APP | CALCR 3275/4885CRHR1 3129/4885CRHR2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.